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We have developed a rapid and simple molecular test,
the IsoGlow HSV Typing assay, for the detection and
typing of herpes simplex virus (type 1 and 2) from
genital or oral lesions. Clinical samples suspended in
viral transport mediums are simply diluted and then
added to a helicase-dependent amplification master
mix. The amplification and detection were performed
on a portable fluorescence detector called the FireFly
instrument. Detection of amplification products is
based on end-point analysis using cycling probe tech-
nology. An internal control nucleic acid was included
in the amplification master mix to monitor the pres-
ence of amplification inhibitors in the samples. Be-
cause the device has only two fluorescence detection
channels, two strategies were developed and com-
pared to detect the internal control template: internal
control detected by melting curve analysis using a
dual-labeled probe, versus internal control detection
using end-point fluorescence release by a CPT probe
at a lower temperature. Both have a total turnaround
time of about 1 hour. Clinical performance relative to
herpes viral culture was evaluated using 176 clinical
specimens. Both formats of the IsoGlow HSV typing
assay had sensitivities comparable to that of the Food
and Drug Administration–cleared IsoAmp HSV (BioHelix
Corp., Beverly MA) test and specificity for the two types
of HSV comparable to that of ELVIS HSV (Diagnostic
Hybrids, Athens, OH). (J Mol Diagn 2012, 14:569–576;
http://dx.doi.org/10.1016/j.jmoldx.2012.05.005)
Two herpes simplex viruses (HSV), HSV-1 and HSV-2, are
common and contagious viruses that cause blistering
and sores on the mouth, lips, or genitals. As such, genital
herpes is one of the most prevalent sexually transmitted
diseases (STDs). The pattern of recurrence of genital
infection is substantially different for the two types, with
recurrences and asymptomatic viral shedding being
much more common in patients infected with HSV-2.1–3Therefore, typing this virus is important, as it can influ-
ence prognosis and counseling of patients.
The IsoAmp HSV assay, recently cleared by the Food
and Drug Administration (FDA), provides a rapid and
simple near-patient diagnostic for the detection of HSV in
genital and oral lesion specimens from symptomatic pa-
tients.4 The assay combines helicase-dependent ampli-
fication (HDA) technology, and a single-use, handheld
detection device (BESt cassette) for end-point detec-
tion.5–7 The overall assay process consists of sample
preparation by a one-step dilution, isothermal nucleic
acid amplification, and detection on the disposable cas-
sette. Results are available within 1.5 hours. However, the
assay does not differentiate between HSV-1 and HSV-2.
Although the BD ProbeTec Herpes Simplex Viruses
(HSV-1 and -2) Qx amplified DNA assay, and the EraGen
MultiCode-RTx HSV 1&2 kit provide HSV typing resolu-
tion, these assays depend on expensive instruments with
large countertop footprints that may not be suitable for
near-patient diagnostics or resource-limited settings.
This creates a substantial market need for a low-cost,
point-of-care HSV typing assay.
In this study, we developed a rapid HSV typing assay
called IsoGlow HSV Typing, by modifying the IsoAmp
HSV test to adapt it to the FireFly instrument (BioHelix,
Beverly, MA). The FireFly instrument offers an option for
portable and cost-efficient fluorescence detection. With
on-board computer software, the device can be used for
both real-time and end-point data acquisition. Although
some isothermal amplification technologies have been
adapted to the similar device recently,8 this is the first
report of it being used for detecting HDA products. As
this instrument has only two detection channels (FAM and
TAMRA), and its dynamic range is narrower than that of
the much more expensive real-time PCR instrument, we
had to devise two novel strategies for the detection of two
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both strategies, cycling probe technology (CPT) was
used for end-point detection of the HSV products ampli-
fied by HDA. CPT uses a chimeric DNA-RNA-DNA probe
that is cut by RNase H when it is bound to its comple-
mentary target sequence.9 In our assay, we use a ther-
mostable RNase H2 (BioHelix Corp.) that specifically
cleaves chimeric probes containing a single RNA mono-
mer when it is bound to a target DNA. Hou and col-
leagues10,11 used this type of RNase H2 for genotyping
single nucelotide polymorphisms with a microplate
reader. In one strategy, we used a postamplification melt-
ing curve analysis to detect this control, while in another
strategy we detected fluorescence released from a CPT
probe after amplification, at a different temperature than
that used during amplification (hereafter defined as two-
step CPT). The relative performance of these two strate-
gies was compared with a set of 176 clinical samples.
Materials and Methods
Reagents
All of the chemicals used in this study were from Sigma-
Aldrich (St. Louis, MO). Restriction endonucleases were
purchased from New England Biolabs (Ipswich, MA).
IsoGlow HSV enzyme reagent, IsoGlow HSV amplification
reagent, and all of the other HDA reagents were from
BioHelix Corp. All of the oligonucleotides were ordered
from IDT (Coralville, IA).
Purified Viral DNA and Assay Standard
Quantified HSV-1 or HSV-2 viral DNA from Advanced
Biotechnologies Inc. (Columbia, MD) were used as a
gold standard. The concentrations of HSV-1–positive or
HSV-2–positive control plasmid from IsoAmp HSV were
determined and were verified by quantitative polymerase
chain reaction (qPCR) using the gold standard and the
same primer pairs of HDA. The qPCR was performed with
DyNAmo HS SYBR Green qPCR Kit with 400 nmol/L of
each primer per reaction (25 L per reaction). The qPCR
assay was performed in a ABI 7300 with the following
program: 15 minutes of 95°C, and then 40 cycles of 10
seconds at 94°C, 30 seconds at 55°C, 30 seconds at
72°C (with fluorescence data collection), and 3 minutes
of 72°C for a final extension followed by melting curve
analysis. The IsoGlow HSV typing assays were initially
optimized with HSV-1 and HSV-2 control plasmid, and
were finally validated with quantified HSV-1 or HSV-2
viral DNA.
Collection, Shipping, and Storage of Clinical
Samples
Sixty clinical samples in viral transport media were col-
lected from Laboratory Alliance of Central New York (Syr-
acuse, NY). A total of 116 clinical swabs suspended in
vial transport medium were collected from the Cleveland
Clinic (Cleveland, OH). The samples were shipped on icefor overnight delivery, and were aliquoted on receipt.
Some were placed at 80°C for long-term storage, and
some were placed at 20°C for short-term storage or
near-term testing.
IsoGlow HSV Typing Assay
The primer pairs used in the IsoGlow HSV assay are the
same as those reported for the IsoAmp HSV kit.4 The
assay was further optimized based on the strategies de-
scribed in the previous publication.12 A thermostable
RNase H2 enzyme (BioHelix Corp.) was added at a con-
centration of 20 ng per assay. For the melting curve
based detection of the IC, the IsoGlow HSV typing am-
plification reagent was prepared as follows: for each as-
say, 60 nmol/L of HSV-1 typing probe, 60 nmol/L of HSV-2
typing probe, and 60 nmol/L of HSVIC melting probe
were combined with the other components in the IsoAmp
HSV amplification reagent (primers and buffers). In the
case of the CPT-based detection of internal control, the
IsoGlow HSV typing amplification reagent were prepared
the same way except that the HSVIC melting probe was
replaced by 80 nmol/L of HSVIC CPT probe. In both
assay formats, the internal control template was pre-
mixed in the amplification reagent.
The IsoGlow HSV typing assays were done using the
following set-up: the reaction master mix was prepared
by combining 40 L of IsoGlow HSV amplification re-
agent, and 5 L of IsoGlow HSV enzyme reagent per
assay. A 5-L quantity of the tested sample was mixed
with the 45-L master mix in 200-L, thin-walled PCR
tubes (Bio-Rad, Hercules, CA), and covered with mineral
oil. The tubes were placed in a FireFly instrument for
amplification and fluorescence detection.
Data Collection Program on FireFly Instrument
For assays in which the IC was detected by melting curve
analysis, the FireFly instrument was programed to follow
the profile:
● Incubate at 35°C for 1 minute with three data col-
lections separated by 20 seconds so as to average the
three readings to obtain an N35 value.
● Incubate at 64°C for 45 minutes with data collection
every minute as an option.
● Incubate 35°C for 2 minutes with data collection
every 30 seconds, such that four data points are aver-
aged to generate the S35 value.
● The FireFly instrument then performs a melting
curve analysis by heating the reaction to 95°C for 1 min-
ute, cooling to 35°C, and raising the reaction to70°C at a
rate of 0.1°C per second, with 1 second of fluorescence
data collection every minute.
The typing results were determined by the signal-to-
noise ratio F (S35/N35), T (S35/N35), and melting curve
analysis from the TAMRA channel; where S represents
end-point reading at the temperature in subscript, N rep-
resents initial-point reading at the temperature in sub-
script, F represents FAM channel, and T represents
TAMRA channel.
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probe, the FireFly instrument was programmed to do the
following profile:
● Incubate at 35°C for 1 minute, and average the
value of three readings taken at 20 second intervals to
get a N35 value.
● Incubate at 64°C for 45 minutes with data collection
every minute, calculating the average of the first four
readings to obtain N64 as well as the average of the last
four readings to obtain S64.
● Incubate at 35°C for 1 minute without data collec-
tion, to allow for binding the maximum number of IC
probes.
● Incubate at 46°C for 10 minutes. Fluorescence is not
read at 46°C because of differences in background at
different temperatures.
● Incubate 35°C for 2 minutes with data collection
every 30 seconds, such that four data points are aver-
aged to generate the S35 value.
The final results were determined by the T (S64/N64), F
(S35/N35), and T (S35/N35) ratios; where S represents end-
point reading at the temperature in subscript, N repre-
sents initial-point reading at the temperature in subscript,
F represents FAM channel, and T represents TAMRA
channel.
Statistical Data Analysis to Determine Cutoff
The fluorescence signal-to-noise ratios obtained from pos-
itive samples and negative samples were grouped using
“Data analysis” in the ToolPak functions of Microsoft (Seat-
tle, Washington) Excel 2010 software. The functions of “His-
togram” and “Descriptive statistics” were used for data dis-
tribution analysis. Themean and SD of signal-to-noise ratios
(S/N) were calculated to determine the corresponding cut-
off. Generally, the cutoff was set as the mean of S/N from
negative samples plus at least three to 10 times the value of
the SD on the S/N from negative samples. The extent of the
separation of the S/N for positive samples versus that of
negative samples was determined empirically with training
samples, and varied for each probe.
Feasibility Study with Clinical Samples
A 5-L quantity of viral transport medium was mixed
together with HSV dilution buffer. Five microliter of the
diluted sample was mixed together with the 45-L master
mix prepared as described in the previous section. The
tubes were placed in a FireFly instrument for amplification
and detection. The results were reported based on the
predetermined decision algorithms. The algorithm for the
assay with IC detection with melting-curve analysis used
the equation F (S35/N35)  2.5 or T (S35/N35)  2.5, to
report positive samples. Only samples that failed to yield
ratios greater that the aforementioned cutoffs were sub-
jected to melting-curve analysis. In those cases, if a de-
tectable fluorescence peak was observed between 47°C
and 55°C during the melting-curve profile with the
TAMRA channel, the sample was reported as being HSV
negative; otherwise, it was reported as an invalid test. Inassays where the IC was detected with a two-step CPT,
the equation F (S35/N35)  2.5 or T (S64/N64)  1.5 was
used to distinguish positive samples for either HSV-1 or
HSV-2. Only if none of the ratios passed the cutoff was
the ratio of T (S35/N35) considered. If T (S35/N35)  1.8,
the sample was reported as “HSV negative.” Samples
that failed to meet the aforementioned cutoff were re-
ported as having yielded invalid test results.
Results
Implementation of Cycling Probe Technology
with HDA
To adapt HDA detection to the FireFly fluorescence
reader, several detection platforms have been developed
and evaluated on the simple device. The CPT presented
the most promise than the other target-specific probes
described in the previous publication, including isother-
mal TaqMan and molecular beacon.13 CPT is a simple
signal amplification method with flexible detection choices.
The CPT probe can be designed with a Tm as close to, or
higher than, the temperature of isothermal amplification for
real-time detection. The probe can also be designed with a
Tm lower than the amplification temperature for postampli-
fication detection or end-point analysis. Moreover, the HDA
assay combined with CPT probe had a higher signal-to-
noise ratio, a faster speed and a better sensitivity than that
combined with TaqMan probe or molecular beacon probe
(data not shown). Therefore, we decided to implement CPT
with HDA (CPT-HDA) for developing a rapid and sensitive
HSV typing assay.
In this report, the CPT probes for the HSV-1 and HSV-2
targets were designed to coincide with the location of two
polymorphic sites within the amplicon for typing purpose.
As shown in Table 1, the probes have a Tm near the 64°C
HDA incubation temperature, such as to allow them to
bind to the corresponding complementary sequence ef-
ficiently, and to be cleaved by the RNase H2 enzyme.
The presence of the two polymorphisms between the
type-specific probes makes the detection specific
enough that the probes do not cross-hybridize to the
other target. Figure 1 shows an example of the perfor-
mance of the assay on the FireFly instrument. The FAM
channel detects the amplification and specific cleavage
of the CPT probe for HSV-2 target, while the TAMRA
channel detects the corresponding signal for HSV-1 tar-
Table 1. IsoGlow HSV Probes
Probes Sequences and modifications
HSV-1 typing
probe
5=-/5TYE563/CGTCACCGTTTcG
CAGGTGTG/3BHQ_1/3=
HSV-2 typing
probe
5=-/56-FAM/CGTGACcGTGTCG
CAGG/3BHQ_1/3=
HSVIC melting
probe
5=-/5TYE563/CAAAGAGTCCG
CAC/3BHQ_1/3=
HSVIC CPT
probe
5=-/5TYE563/TACGAAGGCGA
cAAA/3BHQ_1/3=Lower case represents RNA base.
Underlines highlight the polymorphisms between HSV-1 and HSV-2.
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noise. This is the first report of CPT probes being used in
combination with HDA.
Development of IsoGlow HSV Typing Assay on
the FireFly Instrument, with Internal Control
Determined by Melting Curve Analysis
One of the key advantages of HDA over other isothermal
amplification technologies is its ability to use an IC to
detect the presence of amplification inhibitors often found
in clinical specimens. When such inhibitors are present in
a sample collected from an infected patient, assays that
lack an IC test could result in a misdiagnosis of the
patient; however, when assays that have an IC are per-
formed on samples with inhibitors, the usual result in an
invalid test. Indeed, an invalid test is a preferred outcome
compared to a false negative result. Performing an HSV
typing assay on any commercial real-time PCR instru-
ment is relatively straightforward because these instru-
ments typically have more than four fluorescence detec-
tion channels. However, the compact FireFly instrument
has only two detection channels such that there is no
third channel to accommodate IC detection. To solve the
limitations from the device, we devised two strategies to
detect the IC: IC determined by melting curve analysis
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Figure 1. Real-time detection HSV-1 versus HSV-2 on the Firefly instrument
by implementing CPT together with HDA. Fluorescence emission intensity
versus time is charted for HSV-2 detection using the FAM channel (A), and for
HSV-1 detection in the TAMRA channel (B). The reactions charted with the
lines labeled “HSV2 low” contained 50 copies/reaction of HSV-2 DNA, lines
labeled HSV1 high contained 5000 copies per reaction of HSV-1 DNA, the lines
labeled HSV1 low had 50 copies per reaction of HSV-1 DNA, and the lines labeled
NTC (non-template control) contained no HSV DNA. All test results shown were
performed in duplicate.versus IC determined by two-step CPT.The first strategy was developed based on the capa-
bility of melting curve analysis by the device. The IC
probe, HSVIC melting probe, was designed as a dual-
labeled probe, with a Tm of around 51°C without RNA
bases. Therefore, the IC probe cannot bind to the target
at the amplification temperature or be cleaved by the
RNase H2 enzyme at any temperature. The amplified IC
products were detected with the IC probe by performing
a melting curve after the 64°C incubation. An example of
melting curve analysis of internal control is shown in
Figure 2. The reaction mix was optimized and finalized as
described in Materials and Methods.
The data collection program was designed as follows.
Since the dynamic detection range of the TAMRA chan-
nel of the device is wider than that of FAM channel, the IC
probe uses a TAMRA reporter, the same detector as the
HSV-1 probe. Dual-labeled probes have a lower back-
ground noise at a lower temperature because of
quencher effects when in the random-coil configura-
tion.14 Therefore, to avoid misclassifications, such as a
negative result for a positive result, we maximized the S/N
by collecting data at a lower temperature (eg, 35°C)
before (N35), and after (S35) a 45-minute amplification at
64°C. The ratios of fluorescence intensities collected from
the FAM channel F (S35/N35), and from the TAMRA chan-
nel T (S35/N35) were calculated. If the ratio passed a
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Figure 2. Melting curve-based IC detection. A: Fluorescence intensity
charted against the temperature of the reaction. B: First derivative of the rate
of change in fluorescence intensity as a function of the rate of change in
temperature (dF/dT) charted against temperature. The Tm of IC probe is
approximately 51°C. The line labeled HSVIC high represents an assay per-
formed with 5000 copies of input of HSVIC DNA template in the reaction.
The line labeled HSVIC low corresponds to an assay performed with 700
copies of HSVIC DNA template per reaction. In the IsoGlow HSV Typing
assay, we add 700 copies of HSVIC DNA template. The line labeled NTC is
a non-template control containing no HSVIC DNA.
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scribed below), it was reported as “positive” for the cor-
responding analyte. Tests that failed to reach the cutoff of
both channels were determined by a melting curve anal-
ysis at the TAMRA channel. When a detectable fluores-
cence peak was observed between 47°C and 55°C, a
sample was reported as an “HSV negative” sample; oth-
erwise, it was reported as an “invalid test”.
To determine the assay cutoff for each target (HSV1,
HSV2, IC), a set of training samples were used to evalu-
ate the assay. Serial dilutions of HSV-1 and HSV-2 stan-
dards (as low as 30 copies/assay), and equal mixtures of
HSV-1 and HSV-2 standards (competitive inhibition
study) were used as positive training samples. Samples
of dilution buffer or MiliQ water were used as negative
training samples. The F (S35/N35) and T (S35/N35) were
calculated, and then statistically analyzed. A histogram
was used to view the distribution of F (S35/N35) and T
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Figure 3. Example of the two-step CPT strategy for detecting the IC. The
chart shows the fluorescence intensity of an assay containing 5000 copies/
reaction of HSV-1 DNA, labeled HSV-1 control, as well as different copies of
internal control at multiple temperatures. The lines labeled HSVIC high and
HSVIC low are from assays performed with 5000 copies and 700 copies of the
IC, respectively. Data collection stages are divided into five stages. In stage 1,
incubation was at 35°C for 1 minute with data collection every 20 seconds. In
stage 2, incubation was at 64°C for 45 minutes with data collection every 1
minute. In stage 3, incubation was at 35°C for 1 minute with data collection
every 20 seconds. In stage 4, incubation was at 46°C for 10 minutes with data
collection every minute. In stage 5, incubation was at 35°C for 2 minutes with
data collection every 30 seconds.
Table 2. Performance of IsoGlow HSV Assay on 176 Clinical Sam
Melting Curve Analysis
HSV type 1 comparison
Reference method
Positive Negative
IsoGlow HSV assay
Positive 36 0
Negative 0 140
Total 36 140
Value 95%
Sensitivity 100% 90.4%
Specificity 100% 97.3%100.0%(S35/N35) data from a group of known positive and neg-
ative samples. The mean and SD were used for cutoff
determination based on the data distribution, as de-
scribed in Materials and Methods. From the statistical
analysis, the cutoff was determined to be a ratio of 2.5 for
both detectors. When there was no HSV target in the
sample, only the internal control was amplified with the
ratio of T (S35/N35) in the range of 1.5–2. The increased
signal was from the probe hybridization to the target only,
similar to that of a molecular beacon probe.14
The analytical sensitivity study showed that the devel-
oped assay has a LoD of 10 copies per assay for either
HSV-1 or HSV-2 target. Competitive inhibition was not
observed at any of the concentrations tested (from high
to as low as 30 copies per assay) when the concentra-
tions of HSV-1 and HSV-2 were equal. However, when
HSV-1 was present at more than 500 copies per assay
alongside 50 copies of HSV-2, there was competitive
inhibition of the amplification of HSV-2. A similar phenom-
enon was observed for the test with a 10-fold excess of
HSV-2 versus HSV-1.
Development of IsoGlow HSV Typing Assay
on the Firefly Instrument, Internal Control Is
Determined by Two-Step CPT
Using a melting curve to detect the IC adds 20 minutes to
the test procedure when it is performed by the FireFly
instrument. In contrast, detecting the IC with a CPT probe
that binds at a lower temperature can require less time,
because the assay can be optimized independent of the
device. In the second strategy, the IC was detected using
a CPT probe with a lower Tm than that of the HSV target-
specific probes. The lower Tm of the probe does not
allow it to bind to the IC amplicon during the 64°C incu-
bation of isothermal amplification stage. However, when
the incubation temperature is dropped to a lower temper-
ature (eg, 35°C) after amplification, the IC probe can bind
to the IC template. The incubation temperature of the
reaction is then raised to a higher temperature (eg, 46°C)
to facilitate the cleavage of the bound IC probe by the
thermostable RNase H2.
To make the two-step CPT detection feasible, the Tm of
the IC probe must be at least 10°C below that of the analyte
n Comparison to ELVIS Shell Vial Assay: IC Determined by
HSV type 2 comparison results
Reference method
Total Positive Negative Total
36 36 0 36
140 0 140 140
176 36 140 176
Value 95% CI
100% 90.4%100.0%ples i
results
CI
100.0%
100% 97.3%100.0%
(S64/N6
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has a Tm neighboring 50°C, and contains an RNA base
(Table 1). Therefore, the IC probe cannot bind to the target
to be cleaved by RNase H2 at the amplification tempera-
ture. After amplification, the temperature was lowered to a
temperature that matches the melting temperature of the IC
probe, or even to a lower temperature (such as 35°C) to
increase the probe binding efficiency. Figure 3 shows an
example of IC amplification, and detection by the data col-
lection program. It shows that there is no signal from IC
probe cleavage during amplification stage, and 10-minute
cleavage at 46°C can increase the final signal-to-noise ratio
(T (S35/N35). The reaction mix was optimized, and finalized
as described in Materials and Methods.
Because the FAM channel of the FireFly instrument has
a narrow detection range, the S/N is much higher at 35°C
than at 64°C. Therefore, the data collection for HSV-2 is
performed at 35°C even though there was no other probe
sharing the FAM channel. For HSV-2 and the IC, the noise
data (N35) was collected at 35°C before amplification,
and the signal data (S35) was collected at 35°C after
amplification and the IC cleavage step. For HSV-1, the
noise data (N64) were collected using the first four read-
ings at 64°C and the signal data (S64) was collected at
64°C using the last 4 readings in the amplification incu-
bation. The ratio of F (S35/N35) and T (S64/N64) were
calculated. If the ratios passed the cutoff, it was reported
as “positive” for the corresponding detector. Only if none
of the ratios passed the determined cutoff, was the ratio
of T (S35/N35) considered. If this ratio passed the IC
cutoff, it was reported as “HSV negative” sample; other-
wise, it was reported as “invalid test.”
The cutoff values for the assays using the IC CPT probe
were determined using a similar approach as that used for
the IC melting probe assays. Moreover, the IC cutoff was
verified using blank tests where T (S35/N35) was collected in
assays with no internal control template in the amplification
mix. The blank tests were performed on clean samples
(MiliQ water) or pooled negative clinical samples. Based on
the statistical analysis, the cutoff was determined as the
following: the cutoff of F (S35/N35) is 2.5, the cutoff of T
(S64/N64) is 1.5, and the cutoff of T (S35/N35) is 1.8. Similar
analytical sensitivity and competitive inhibition results were
Table 3. Performance of IsoGlow HSV Assay on 176 Clinical Sam
Step CPT
HSV type 1 comparison
Reference method
Positive Negative
IsoGlow HSV assay
Positive 36 2
Negative 0* 138
Total 36 140
Value 95%
Sensitivity 100.0% 90.4%
Specificity 98.6% 94.9%
*One of the HSV1 positive samples showed as close to the cutoff of Tobserved for this second detection strategy.Evaluation of Two IC Detection Strategies with
Clinical Samples
To compare the clinical performance of the two IC detec-
tion strategies, a preliminary clinical study was performed
on 176 frozen clinical specimens; ie, oral or genital swabs
suspended in viral transport medium. Of the 176 sam-
ples, 36 were HSV-1 positive, 36 were HSV-2 positive,
and 104 were HSV negative, as determined by the ELVIS
HSV test obtained from Diagnostic Hybrids. A total of 116
of the samples were also tested with the FDA cleared,
IsoAmp HSV molecular assay. We found complete agree-
ment between the two assays when the melting-curve–
based IC detection method was used to detect negative
samples with the IsoGlow HSV test.
A summary of the clinical study data are shown in
Table 2 and Table 3. Assays using the melting-curve–
based IC detection strategy were in 100% agreement
with the ELVIS shell vial culture reference method. One of
the HSV-1–positive samples showed evidence of either a
low copy number input, or the presence of possible am-
plification inhibiting substances in the sample. Its real-
time amplification signal collected at 64°C showed linear
amplification instead of the usual exponential increase in
fluorescence intensity. As illustrated in Table 4, this pos-
itive sample had a T (S35/N35) value of 5.5, which is the
smallest of all of the HSV-1–positive clinical samples
n Comparison to ELVIS Shell Vial Assay: IC Determined by Two-
HSV type 2 comparison results
Reference method
Total Positive Negative Total
38 36 1 37
138 0 139 139
176 36 140 176
Value 95% CI
100% 90.4%100.0%
99.3% 96.1%99.9%
4). Some tests slightly pass the cutoff, and some tests show as negative.
Table 4. Summary of Statistical Analysis of the Signal-to-Noise
Ratios (s/n) in Clinical Samples: IC Determined by
Melting Curve Analysis
Detector Range Mean
Standard
deviation
36 HSV-1positive samples, T (S35/N35) cutoff  2.5
TAMRA (35°C) 5.58.3 7.2 0.5
FAM (35°C) 1.11.5 1.2 0.1
36 HSV-2positive samples, F (S35/N35) cutoff  2.5
TAMRA (35°C) 1.31.5 1.3 0.1
FAM (35°C) 4.58.8 7.2 0.7
104 HSV-negative samples, IC determined by melting
curve analysis
TAMRA (35°C) 1.42.4 1.8 0.2ples i
results
CI
100.0%
99.6%FAM (35°C) 1.02.2 1.1 0.2
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more variability during repeated tests where the IC was
detected by the two-step CPT probe. Indeed, some of the
tests were scored as HSV negative whereas others were
scored as positive, but with T (S64/N64) of 1.6, which was
much lower than the other positive samples. Three of the
ELVIS shell vial culture negative samples showed as
HSV-1 or HSV-2 positive only by the method with two-step
CPT. The corresponding amplification signal at 64°C
showed late amplification curve, suggesting they might
be HSV positive with low virus titer. Table 6 compares the
performance between the IsoGlow HSV and IsoAmp HSV
assays on the 116 clinical samples tested by both
assays.
Comparing Table 4 and Table 5, there is no obvious
difference for the data of HSV-2 positive samples be-
tween the two strategies. Table 4 and 5 also shows the
distribution of S/N ratios seen in the clinical study. For
both methods, the cutoff can clearly separate the positive
samples from the negative ones. It fully demonstrates that
the proposed decision algorithms based on the initial
analytical study is feasible. Although the clinical study is
modest in scale, it clearly indicates that either strategy for
detecting the IC is feasible, the strategy with melting
curve analysis has greater tolerance to amplification in-
hibitors present in certain clinical samples, because the
mean signal-to-noise ratios between positive samples
and negative samples are more widely separated.
Discussion
This study is the first to report an HSV typing assay using
a portable device with only two fluorescence detection
Table 5. Summary of Statistical Analysis of Signal-to-Noise Ratio
(s/n) from Clinical Study: IC Determined by Two-Step
CPT
Detector Range Mean
Standard
deviation
38 HSV-1positive samples, T (S64/N64) cutoff  1.5
TAMRA (64°C) 1.6–3.0 2.5 0.3
FAM (35°C) 1.1–1.5 1.2 0.1
37 HSV-2positive samples, F (S35/N35) cutoff  2.5
TAMRA (64°C) 1.0–1.4 1.1 0.1
FAM (35°C) 6.6–7.6 7.1 0.2
101 HSV-negative samples, T (S35/N35) cutoff  1.8
TAMRA (64°C) 1.0–1.4 1.0 0.1
TAMRA (35°C) 1.9–4.8 3.0 0.5
FAM (35°C) 1.0–2.1 1.2 0.2
Table 6. Comparison IsoGlow HSV with IsoAmp HSV Assays wi
HSV pos
Agreement
IsoGlow HSV, IC determined
by melting curve
32/32 (100%)
IsoGlow HSV, IC determined
by two-step CPT
32/32 (100%)*IsoAmp HSV does not provide typing information. The IsoAmp HSV assays are
assays with these 116 clinical samples.channels. It also uses the unique two-step strategy to
detect more analytes than would otherwise be possible if
only one analyte were detected with each channel. Al-
though both two-step methods can increase the multiplex
capacity of the device, the use of melting curve analysis
for IC detection is more robust in the presence of ampli-
fication inhibitors. However, the two-step CPT method
can be more sensitive in some cases. With the two-step
CPT format, the assay signal-to-noise ratio is significantly
increased by the combination of exponential nucleic acid
amplification and linear signal amplification. So far, the
CPT detection format has the best performance for HDA
of all evaluated real-time detection formats based on
target-specific probes. The optimal improvements on the
assay itself dramatically reduce the requirements for in-
strumentation. Therefore, the simple portable fluores-
cence reader can be easily applied for HDA amplification
and detection. With the IsoGlow platform, the overall pro-
cess of nucleic acid amplification, detection and report-
ing can be integrated for automation. This allows it to be
applied not only for small set data analysis (ie, FireFly
instrument) but also for high-throughput data analysis (ie,
96 or more reactions on any commercially available flu-
orescence detector).
In summary, the turnaround time for the IsoGlow HSV
typing assay has been shortened to approximately 1
hour, with a hands-on time of less than 5 minutes, pro-
viding a rapid nucleic acid test for diagnosis of HSV
infections without the limitation of expensive instruments.
This study demonstrates the feasibility of using HDA
combined with end-point analysis on a miniaturized, low-
cost fluorescence detector for rapid HSV detection, and
typing. The FireFly instrument is just one choice of por-
table fluorescence detectors. This isothermal assay
based on HDA can be adapted to other formats of min-
iaturized detectors or integrated minisystems, enabling
the technology to have a great potential for application in
decentralized and/or resource-limited settings.
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HSV negative
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